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The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine field. We
have identified a subtype C HIV-1-superinfected individual, CAP256, with high-level BCN activity, and char-
acterized the antibody specificity mediating breadth. CAP256 developed potent BCN activity peaking at 3 years
postinfection, neutralizing 32 (76%) of 42 heterologous viruses, with titers of antibodies against some viruses
exceeding 1:10,000. CAP256 showed a subtype bias, preferentially neutralizing subtype C and A viruses over
subtype B viruses. CAP256 BCN serum targeted a quaternary epitope which included the V1V2 region. Further
mapping identified residues F159, N160, L165, R166, D167, K169, and K171 (forming the FN/LRD-K-K motif)
in the V2 region as crucial to the CAP256 epitope. However, the fine specificity of the BCN response varied over
time and, while consistently dependent on R166 and K169, became gradually less dependent on D167 and
K171, possibly contributing to the incremental increase in breadth over 4 years. The presence of an intact
FN/LRD-K-K motif in heterologous viruses was associated with sensitivity, although the length of the adjacent
V1 loop modulated the degree of sensitivity, with a shorter V1 region significantly associated with higher titers.
Repair of the FN/LRD-K-K motif in resistant heterologous viruses conferred sensitivity, with titers sometimes
exceeding 1:10,000. Comparison of the CAP256 epitope with that of the PG9/PG16 monoclonal antibodies
suggested that these epitopes overlapped, adding to the mounting evidence that this may represent a common
neutralization target that should be further investigated as a potential vaccine candidate.
The development of an HIV-1 vaccine is widely assumed to
require both a cellular and a neutralizing antibody (nAb) com-
ponent. Despite substantial efforts to produce a vaccine im-
munogen capable of inducing broadly nAb responses, little
success has been achieved (16, 18, 29). The inability to design
an appropriate antigen is hindered by the enormous antigenic
variability, as well as a myriad of masking mechanisms, exhib-
ited by the envelope glycoprotein (5, 19). The identification of
new nAb targets on the HIV-1 envelope, as well as unraveling
how antibodies to these targets develop in natural infection, is
therefore a high priority for HIV vaccinology.
The majority of individuals mount a potent nAb response
within the first few months of HIV-1 infection that largely
targets variable regions of the envelope glycoprotein and is
very type specific (4, 14, 20, 33, 45). However, only a subset of
infected people (20 to 30%) develop broadly cross-neutralizing
(BCN) antibodies effective against diverse heterologous vi-
ruses (23, 35, 38, 39). The concerted efforts by numerous
groups to understand the polyclonal specificities of these BCN
plasmas have defined the contributions of antibodies against
known targets such as the CD4 binding site, CD4-induced
epitopes, and the membrane-proximal region (MPER), as well
as unknown targets on gp120 and gp41 (6, 11, 23, 35, 38, 39).
Identification of the targets of such BCN antibodies is crucial,
as these epitopes likely represent novel vaccine targets that
may be more amenable to vaccine design than current targets,
many of which have been defined on the basis of the specific-
ities of a few well-characterized monoclonal antibodies
(MAbs) (e.g., 4E10, 2F5, IgG1b12, and 2G12) (5).
The existence of quaternary neutralizing epitopes (QNEs),
those that are present only within the context of a native
trimeric envelope “spike,” was first demonstrated by the iso-
lation of MAb 2909, which binds an epitope encompassing
parts of the V2 and V3 loops but does not bind monomeric
gp120 (10, 17). Similar neutralizing MAbs from rhesus ma-
caques infected with simian/human immunodeficiency virus
SF162P4 (2.2G, 2.3E, and 2.5B) target the same overall QNE,
though each possesses distinct amino acid and glycan require-
ments (34). Although these antibodies are very potent, they are
also extremely type specific, neutralizing only SF162. However,
the isolation of MAbs PG9 and PG16, somatic variants isolated
from an HIV-1 subtype A-infected individual, which recognize
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QNEs and show substantial breadth and potency across sub-
types, confirmed the notion that BCN antibodies against these
types of epitopes exist and possibly define a valuable new
vaccine target (43).
The epitope recognized by PG9/PG16 is dependent on the
N160 glycosylation motif in V2, as well as other residues in the
stem of V1/V2, V2, and V3 (with PG16 showing much greater
dependence on residues in V3 than PG9) (43). PG9/PG16-like
antibodies are increasingly being defined as those that are not
generally adsorbed by gp120 and are sensitive to mutations at
N160 and to treatment with kifunensine (a mannose analogue
that inhibits -mannosidases in the type 1 endoplasmic retic-
ulum and the Golgi apparatus) (7, 44). The binding of such
antibodies to a region largely described as highly variable con-
firms the fact that within V2 there are regions and residues that
are highly conserved, even between different subtypes (48).
Crystallographic and structure-function analyses of PG16 iden-
tified extensive affinity maturation and an unusually long com-
plementarity-determining region (CDR) H3 (28 residues)
comprising nearly half of the CDR surface and forming a
stable, axe-shaped subdomain that protrudes from the anti-
body as critical to its broad neutralization capacity (27, 28).
This raises the questions of whether such antibodies would be
hard to elicit in natural infection and whether they would
require several years of antigen exposure to develop (27, 28).
The prevalence of BCN antibodies targeting QNEs is un-
known. The fact that several studies mapping polyclonal sera
(using reagents that are often based on monomeric gp120 and
peptides) have been unable to account for the total neutraliz-
ing capacity of BCN plasma suggests that many BCN antibod-
ies recognizing QNEs may have gone undetected. Binley et al.
(1), using a subset of 8 of 24 subtype B and C sera, showed that
anti-gp120 antibodies accounted for a significant but variable
fraction of neutralization, depending on the isolate against
which adsorbed serum was tested. Similarly Walker et al. (44)
reported the possibility of BCN antibodies against QNEs (on
the basis of a lack of adsorption using monomeric gp120) in 8
of 18 individuals with BCN activity, with some of these nAbs
better adsorbed by a YU-2 gp140-foldon trimer. In the Centre
for the AIDS Programme of Research in South Africa
(CAPRISA) Acute Infection cohort of subtype C-infected in-
dividuals, 4/7 BCN individuals from a total of 40 subjects ap-
pear to have antibodies recognizing QNEs (data not shown).
These data suggest that these types of antibodies may occur
quite frequently.
Here we describe the development of V2-dependent QNE
antibodies in CAP256, a subtype C-infected (and later super-
infected) individual in the CAPRISA Acute Infection cohort
(42) who developed unusually high-titer nAbs directed primar-
ily at subtype C and A viruses. We have mapped the precise
residues crucial for the formation of this V2-dependent qua-
ternary BCN epitope and the variation in the fine specificity of
the BCN response that occurred over 4 years of infection.
These data point to this region of V2 as being sufficiently
conserved and immunogenic to elicit BCN antibodies.
MATERIALS AND METHODS
CAPRISA participant CAP256. CAP256 was enrolled in the CAPRISA Acute
Infection study (42) that was established in 2004 in Durban and Vulindlela,
South Africa. The CAPRISA Acute Infection study was reviewed and approved
by the research ethics committees of the University of KwaZulu-Natal (E013/04),
the University of Cape Town (025/2004), and the University of the Witwa-
tersrand (MM040202). All participants provided written informed consent for
study participation.
Cell lines. The JC53bl-13 cell line, engineered by J. Kappes and X. Wu, was
obtained from the NIH AIDS Research and Reference Reagent Program. 293T
cells were obtained from George Shaw (University of Alabama, Birmingham).
Both cell lines were cultured in Dulbecco’s modified Eagle medium (Gibco BRL
Life Technologies) containing 10% heat-inactivated fetal bovine serum and 50
g/ml gentamicin (Sigma). Cell monolayers were disrupted at confluence by
treatment with 0.25% trypsin in 1 mM EDTA.
Neutralization assays. Env-pseudotyped viruses were obtained by cotransfect-
ing the Env plasmid with pSG3Env (45) using Fugene transfection reagent
(Roche) as previously described (14). Neutralization was measured as described
previously (14) by a reduction in luciferase gene expression after single-round
infection of JC53bl-13 cells with Env-pseudotyped viruses. Titers were calculated
as the reciprocal plasma dilutions causing a 50% reduction in the number of
relative light units (ID50).
rgp120 production and purification. The consensus C (ConC) plasmid
pConCgp120-opt (catalog no. 11405), obtained through the AIDS Research
and Reference Reagent Program from Beatrice Hahn, was transfected into
293T cells using TransIT-LT1 (Mirus, Pittsburgh, PA). The supernatant was
collected after 4 days for purification of recombinant gp120 (rgp120). gp120
was isolated using Galanthus nivalis lectin agarose matrix (Sigma-Aldrich, St.
Louis, MO) and eluted with 0.5 M methyl--D-mannopyranoside (Sigma).
The remaining supernatant was passed over the agarose matrix a further
three times before ConC rgp120 was concentrated using an Amicon Centri-
con filter with a molecular weight cutoff of 30,000. The purified rgp20 was
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Serum adsorption of anti-gp120 antibodies from CAP256 plasma. Purified
rgp120 was coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia
Biotech, Uppsala, Sweden) overnight at 4°C before washing away of unbound
protein with phosphate-buffered saline (PBS) containing 0.5 M NaCl. Beads
were blocked with 1 M ethanolamine (pH 8.0) for 2 h and washed three times,
alternating between 0.1 M CH3COONa (pH 4.0)–0.5 M NaCl and 0.1 M Tris
(pH 8.0)–0.5 M NaCl, before a final wash with PBS. Coated beads were used to
adsorb anti-gp120 antibodies as follows. CAP256 plasma was diluted 1:10 in PBS,
and 100 l was added to the coated beads and incubated overnight at 4°C.
Adsorbed plasma was removed and stored. Beads were washed twice with 1 ml
PBS, which was also collected and combined with the flowthrough. Fetal bovine
serum (400 l) was added before concentration of the adsorbed plasma back
down to 500 l using an Amicon Ultra 4 filter unit (molecular weight cutoff,
30,000). Anti-gp120 binding capacity was measured by enzyme-linked immu-
nosorbent assay (ELISA) as described below. Neutralization assays using ad-
sorbed material were performed in the Pinter lab with U87 cells as described
previously (17).
gp120 binding ELISA. ConC rgp120 (100 ng/well), JRFL rgp120 (50 ng/well),
and IIIB lysate (200 ng/well; ENI Diagnostic, Inc., Silver Spring, MD) was used
to coat 96-well ELISA plates in sodium bicarbonate buffer, pH 9.8, overnight at
4°C. After blocking with 2% Blotto in PBS (pH 7.4) at 37°C for 30 min, serial
dilutions of adsorbed CAP256 plasma (and unadsorbed plasma) were added to
the plate. After incubation for 60 min at 37°C, plates were washed and bound
antibodies were detected using a 1:2,000 dilution of alkaline-phosphate conju-
gated anti-human IgG (Zymax), followed by addition of substrate (1 mg/ml
p-nitrophenol in diethanolamine buffer [pH 9.8]). Absorbance (405 nm) mea-
surements were taken after 30 min using a Spectra SLT ELISA plate reader
(TECAN Instruments, Research Triangle Park, NC).
Generation of chimeras and mutant envelopes. Chimeric V1V2 Envs were
created using an overlapping PCR strategy with the inserts and flanking regions
amplified in separate reactions. After linkage, the 3-kb chimeric PCR fragments
generated using primers EnvAdir and EnvM (9) were cloned into pCDNA 3.1
(directional; Invitrogen) and screened for function as previously described (12).
In some cases, small regions of V2 were exchanged by the insertion of synthetic
oligonucleotides at unique restriction sites engineered into the V2 region. Chi-
merism was confirmed by sequence analysis. Site-directed mutagenesis was per-
formed using the Stratagene QuikChange II kit (Stratagene).
RESULTS
Development of high-titer cross-nAbs in CAP256 that pref-
erentially neutralize subtype C viruses. CAP256, a participant
in the CAPRISA Acute Infection cohort, was infected with an
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HIV-1 subtype C virus in July 2005 and subsequently superin-
fected 13 to 15 weeks later with an unrelated second subtype C
virus (data not shown). She had a median viral load of 105,000
RNA copies/ml over 4.5 years of infection, peaking at
2,390,000 RNA copies/ml at the time of superinfection, with
steadily declining CD4 counts (Fig. 1). In November 2009, she
was diagnosed with and treated for extrapulmonary tubercu-
losis and started on antiretroviral (ARV) therapy in January
2010, 4 years 7 months postinfection (p.i.). She was one of 7
women from this cohort of 40 who at 3 years of infection
showed a high level of cross-neutralizing antibody activity
(data not shown).
The development of neutralization breadth in CAP256 was
assessed by testing serum/plasma at 1 (visit 16), 2 (visit 20), 3
(visit 24), and 4 (visit 28) years p.i. (prior to her initiation on
ARV therapy) against a panel of 42 heterologous pseudovi-
ruses (Fig. 2). This included pseudoviruses from the tier 2
subtype A, B, and C panels (21, 22) and pseudoviruses derived
FIG. 1. CAP256 viral loads and CD4 T cell counts over 4 years of
infection. Key time points for neutralization assays at 1, 2, 3, and 4
years p.i. are indicated with dotted lines. The peak viral load (VL) at
the point of superinfection and the time point at which CAP256 was
started on ARV therapy are shown by arrows. v16, visit 16, etc.
FIG. 2. Development of cross-nAbs against heterologous viruses of subtypes A, B, and C in CAP256 over 1 to 4 years of infection. Titers shown
are ID50.
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from the CAPRISA Acute Infection cohort (14). CAP256 de-
veloped substantial neutralization breadth over time, with
cross-nAbs increasing incrementally for the first 3 years. Thus,
heterologous neutralization was detectable as early as 1 year
but was limited to 7/42 (17%) viruses, increasing to 22/42
(52%) viruses at 2 years, and peaking at 3 years with activity
against 32/42 (76%) viruses. Although nAb titers overall de-
clined slightly at 4 years of infection, the percentage of viruses
neutralized remained static (32/42, 76%). CAP256 showed a
distinct subtype bias, preferentially neutralizing subtype C and
A viruses (P  0.0011 and P  0.0268, respectively) over
subtype B viruses. At the peak of BCN activity, measured at 3
years p.i., 88% (21/24) of subtype C viruses were neutralized at
a median ID50 titer of 1:968. Unusually high titers against some
subtype C viruses were observed, with titers against ConC
exceeding 1:10,000 and even 1:44,000. Subtype A viruses
were also frequently neutralized, with 5/6 viruses (83%) neu-
tralized at a median titer of 1:658 at 3 years p.i. Titers against
subtype A viruses, however, did not reach the levels observed
against many subtype C viruses, with a measured maximum
titer of antibody against Q168 of 1:2,349. In stark contrast to
both subtypes A and C, subtype B viruses were neutralized far
less frequently (only 6/12 viruses at 3 years p.i.), and in many
cases, the nAb titers were marginal, with a median titer of only
1:47 and a maximum of 1:788 against 6535, which is a tier 1B
virus that is relatively neutralization sensitive (37). Therefore,
CAP256 developed potent cross-nAbs that preferentially neu-
tralized viruses of subtypes A and C, with activity accumulating
gradually and peaking at 3 years of infection.
CAP256 BCN antibodies were not adsorbed by gp120. To
assess whether the epitopes recognized by CAP256 plasma
antibodies at 3.25 years (visit 25) were present on the mono-
meric gp120 structure, we used rgp120 from the ConC enve-
lope, which was highly sensitive to these antibodies. Adsorp-
tion of CAP256 plasma using gp120 bound to Sepharose beads
resulted in a significant decrease in the levels of gp120 binding
antibody in the flowthrough as measured by ELISA against
ConC gp120 and JR-FL gp120 (Fig. 3A). Binding of adsorbed
plasma to the IIIB viral lysate, consisting mostly of viral core
proteins, was unaffected, as expected. However, gp120 deple-
tion had no effect on the neutralization activity of this plasma
sample against heterologous viruses ConC and ZM53M or the
CAP256 autologous enrolment virus (CAP256.1mo.C7) (Fig.
3B). ConC gp120-adsorbed plasma did, however, show re-
duced neutralization activity against SF162, reflecting the ad-
sorption of antibodies that are able to neutralize this tier 1
virus (Fig. 3B). These data suggested that the BCN antibodies
in CAP256 recognized quaternary epitopes dependent on the
trimeric form of the envelope glycoprotein, which could not be
depleted with gp120.
The QNE in CAP256 involves the V1V2 region. We have
previously described the construction of variable-loop chimeric
viruses used to map the specificities of antibodies mediating
autologous neutralization (25, 26). Here we have made use of
chimeras consisting of CAP45 (neutralized by CAP256 at high
titer) and CAP84 (not neutralized at 2 years p.i., Fig. 2) to map
heterologous neutralization. Chimeras that contained the
V1V2, C3V4, V4, and V5 regions of CAP45 in the CAP84-
resistant backbone were used to localize the region targeted by
the QNE antibody in CAP256. Figure 4 shows that plasma
from CAP256 at 2 years p.i. (visit 20) neutralized CAP45 at an
ID50 of 1:7,898 but failed to neutralize CAP84 (ID50 of less
than 1:45). Transfer of the CAP45 V1V2 region into CAP84 to
produce the 84-45-84 V1V2 region chimera resulted in neu-
tralization sensitivity, reflected in a titer of 1:5,075 (Fig. 4). In
contrast, all of the other chimeras (C3V4, V4, and V5) were
FIG. 3. Effect of rgp120 adsorption on CAP256 neutralization. (A) Binding of CAP256 plasma and rgp120-adsorbed plasma on binding to
ConC rgp120, JRFL rgp120, and IIIB viral lysate measured by ELISA (optical density [OD] at 405 nm). (B) Neutralization by CAP256 plasma and
ConC rgp120-adsorbed CAP256 plasma of ConC, ZM53M, autologous virus CAP256.1mo.C7, and SF162.
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completely resistant to neutralization (titers of 1:45). This
suggested that heterologous neutralization of the CAP45 pseu-
dovirus was mediated by V1V2 region-dependent antibodies
present in CAP256 serum.
To assess whether CAP256 cross-neutralization of other vi-
ruses was also mediated by antibodies dependent on the V1V2
region and whether this remained the case over the duration of
infection, we constructed nine additional V1V2 region chime-
ras, transferring the V1V2 region from sensitive heterologous
viruses into a resistant backbone (either CAP88 or CAP84). In
addition to CAP45 shown above, we included two subtype C
viruses neutralized at extremely high titers by 1 year p.i.
(CAP210 and ConC), as well as five subtype C viruses neutral-
ized at much lower titers at 2 to 3 years p.i. (CAP239, CAP206,
ZM109, CAP61, and CAP255) (Fig. 2). In order to assess
whether subtype A viruses were also neutralized via the V1V2
region, we constructed chimeras using two subtype A viruses
that were neutralized by plasma from 2 years p.i. Although we
constructed chimeras for sensitive subtype B viruses (6535 and
WITO), they were nonfunctional and could not be used in
neutralization assays.
All chimeras were tested along with both parental viruses
against longitudinal plasma spanning 4 years of infection. In 9
of 10 heterologous viruses (including CAP45), antibodies de-
pendent on the V1V2 region were shown to mediate neutral-
ization over the entire time span. This was reflected by acqui-
sition of sensitivity of the resistant backbone (CAP84 or
CAP88) into which the V1V2 region of each heterologous
virus was introduced (Fig. 5). This confirmed that for the
majority of the heterologous viruses, neutralization was medi-
ated by cross-reactive V1V2 region-dependent antibodies in
CAP256 plasma.
For one virus, CAP255, transfer of the V1V2 region into an
insensitive backbone failed to transfer neutralization sensitivity
(Fig. 5, gray shading). This suggested that CAP255 was neu-
tralized not by anti-V1V2 region antibodies in CAP256 plasma
but rather by different specificities targeting a region outside
the V1V2 loops. The neutralization of CAP255 by CAP256
serum was of low titer even at 3 years of infection, similar to
the profile of many of the subtype B viruses (Fig. 2). Interest-
ingly, gp120 adsorption of CAP256 serum did not affect the
neutralization of CAP255 (data not shown), suggesting that the
antibody specificity mediating neutralization of this virus may
also target a quaternary epitope within the trimeric form of the
envelope.
The kinetics of the neutralization curves suggested that
cross-neutralization was mediated in three waves, with the first
appearing at 1 year p.i. and targeting the V1V2 region of
CAP45, CAP210, and ConC (Fig. 2 and 5) and the second
wave targeting the V1V2 region of subtype C viruses CAP239
and CAP206 and subtype A virus Q23. A third low-titer anti-
V1V2 region response against ZM109 and CAP61, as well as
subtype A virus Q168, emerged some months later. V1V2
region-dependent antibodies, as measured by the titers of an-
tibodies against chimeric constructs, generally accounted for
close to 100% of the parental neutralizing activity, suggesting
that heterologous neutralization was restricted to antibodies
recognizing this region. The consistent involvement of the
V1V2 region in three waves of cross-neutralizing activity sug-
gested the possibility that either multiple anti-V1V2 region
antibodies developed in CAP256 over time or affinity matura-
tion of a single nAb resulted in an expanded cross-neutralizing
antibody response.
Mapping of the precise residues in the V1V2 region targeted
by CAP256 antibodies. Since the V1 loop is considerably more
variable that the V2 loop (48), we hypothesized that the BCN
antibodies in CAP256 were most likely directed at V2. We
therefore made use of subdomain V2 loop chimeras (V2-left or
V2-middle) consisting of a resistant virus (JR-FL) and a highly
sensitive virus (ZM53M) (Fig. 6A). When the V2-L region
from JR-FL (N156 to R166, spanning the N160 glycan site)
was transferred into the ZM53M virus, there was a decrease in
neutralization sensitivity. When the V2-M region (D167 to
D180) was transferred, the chimera became almost completely
resistant (Fig. 6A). This finding demonstrated that determi-
nants of CAP256 sensitivity were located in both V2-L and
V2-M, with residues 168 to 172 in V2-M making major con-
tributions to the epitope.
The precise residues involved in CAP256 neutralization
were mapped more precisely by alanine scanning of the V2
region in ConC and ZM53M pseudoviruses. Plasma from visit
18 (82 weeks p.i.) was tested against ConC V1V2 region point
mutants (selected data are shown in Fig. 6B), and plasma from
visit 19 (94 weeks p.i.) was tested against ZM53M mutants
(data not shown). In the ConC backbone, the most dramatic
abrogation of CAP256 plasma neutralization was achieved
through mutations at positions 166 and 169. For R166A, there
was a 100-fold (98%) titer reduction, from 1:14,057 to
1:137, while for K169E, there was a 79-fold titer reduction to
1:179 (Fig. 6B). In addition, there was an 8-fold (90%) or
greater reduction in the titers of antibodies against the ConC
F159A (to 1:931), N160A (1:1780), L165A (1:966), D167N
(1:1139), and K171A (1:1339) mutants. Overall, this antibody
(or antibodies) appears to be dependent on F159, N160, L165,
R166, D167, K169, and K171 (which is from here on referred
to as the FN/LRD-K-K motif). Similar results were obtained
for the ZM53M mutants, although in this backbone the de-
pendence on N160 was not observed, and in fact there was a
slight increase in titer (1:23,000) compared to that of wild-type
ZM53M (1:14,800) (data not shown).
The discrepancy between the chimeras (Fig. 6A), which sug-
gested that the V2-L region contributed only slightly to the
CAP256 epitope, and the alanine scanning data (Fig. 6B),
FIG. 4. CAP256 plasma neutralizes CAP45 via a V1V2 region-
dependent antibody. Neutralization of chimeric viruses constructed of
CAP45 (sensitive) and CAP84 (resistant) is shown. Only the chimera
containing the V1V2 region of CAP45 was sensitive to neutralization.
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FIG. 5. V1V2 region-dependent antibodies mediate cross-neutralization of subtype C and A viruses. Chimeric viruses containing the V1V2
region of sensitive subtype C or A viruses were tested against longitudinal plasma samples spanning 4 years of infection. Sensitive parental viruses
are shown by black lines, gray lines denote resistant (backbone) viruses, and gray squares with black outlines are V1V2 region chimeras. Asterisks
indicate graphs with differing scales to illustrate lower titers.
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which showed the importance of, among others, the R166
residue (in the V2-L region), is likely due to the fact that both
JR-FL and ZM53M contain an arginine residue at position
166. Therefore, swapping the V2-L region does not result in a
dramatic change in titer in this case.
Changes in the fine specificity of the BCN anti-V2 antibody
over time. The mapping of the FN/LRD-K-K motif shown in
Fig. 6 was performed using a single time point (visit 18, 82
weeks p.i.). Given that titers measured against CAP45 showed
three distinct peaks at 82 weeks (titer of 1:5,555), 134 weeks
(1:10,414), and 176 weeks (16,562) p.i. but remained exclu-
sively targeted at the V1V2 region, with the titers against the
chimera consistently mirroring those of the parental virus (Fig.
5), we queried whether there were changes in the fine speci-
ficity of this BCN antibody (antibodies) over time. Longitudi-
nal plasmas from enrolment up to 4 years of infection were
tested against CAP45 viruses containing mutations at all of the
residues that make up the FN/LRD-K-K motif (F159A,
N160A, L165A, R166A, D167N, K169E, and K171E). From
the point at which breadth developed (approximately 1 year
p.i.) through to 4 years p.i., the anti-V2 QNE antibody was
consistently highly dependent on the R166 and K169 resi-
dues, with titers dropping more than 40-fold, from greater
than 1:4,000 to between 1:45 (no neutralization) and 1:100
(Fig. 7).
In contrast, the antibody was variably dependent on the
other residues over time. The L165A mutation abrogated neu-
tralization during the early stages of infection, with the peak at
82 weeks reduced from a titer of 1:5,555 to 1:45. However,
from 100 weeks onward, the dependence of the sera on the
L165 residue was reduced, with titers rising to become similar
to those of antibodies against the parental virus and then
declining slightly by the third peak (to a titer of 1:3,771 at 176
weeks p.i.). Sensitivity to the K171E mutation was also limited
to the earlier time points (100 weeks)—this mutation entirely
abrogated neutralization during the first peak but had a less
dramatic effect on the second peak of neutralization (with a
titer of 1:1,500 at 134 weeks p.i.) and even less of an effect on
later neutralization (titer of 1:7,529 at 193 weeks p.i.). The
D167N mutation prevented neutralization at both of the ear-
lier peaks, but by the third peak at 176 weeks p.i., titers rose to
1:3,000, reflecting decreased dependence on the D167 residue.
The N160A mutation had a significant effect on neutralization
throughout the 4-year period, with neutralization abrogated
during the first 2 years and thereafter rising slightly to titers of
approximately 1:500, suggesting consistent involvement of this
FIG. 6. Identification of the FN/LRD-K-K motif in V2 as a major target of CAP256 plasma neutralizing activity. (A) V2-L and V2-M domain
swap chimeras consisting of the ZM53M (sensitive) and JRFL (resistant) viruses. Shown at the top are residues in the sequences of the V2L and
V2M regions of ZM53M and JRFL and the chimeras. The graph at the bottom shows the neutralization of the ZM53M and chimeric viruses
containing the V2L or V2M domain from the JRFL virus, confirming the importance of both regions, but especially the V2M region, in forming
the CAP256 epitope. (B) Site-directed mutagenesis of residues in V2 was used to map critical residues in the ConC background. Black highlighting
denotes 75-fold titer reductions, dark gray denotes mutations resulting in 8-fold titer reductions, and light gray denotes 3-fold titer reductions.
The FN/LRD-K-K motif represents residues affecting the CAP256 titers by more than 8-fold. Two other residues (168 and 181, not included in
the motif) had a lesser effect. wt, wild type.
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residue in the formation of the epitope. The effect of the
F159A mutation on neutralization was also relatively consis-
tent over time. Overall, the differing effect of each mutation
reinforced the central role of the R166 and K169 residues in
this epitope but also indicated that there were changes over
time in the fine specificity of the anti-V2 QNE antibody.
The changes in the fine specificity of the CAP256 serum over
time described above may explain the incremental increase in
breadth (Fig. 2), with fewer heterologous viruses neutralized at
year 1 and more neutralized at later time points. In particular,
four of the six subtype C viruses that were neutralization re-
sistant at year 2 but had titers of 1:100 at year 3 had poly-
morphisms at K171 (K171N/R/Q). The reduced dependence of
the later sera on K171 may explain their increase in neutral-
ization sensitivity.
The FN/LRD-K-K motif was associated with but not suffi-
cient for high-titer neutralization in subtype C. We analyzed
the sequences of the heterologous viruses described in Fig. 2,
focusing specifically on the FN/LRD-K-K motif to define the
relationship, if any, between this motif and the neutralization
titer. Among the subtype C viruses, ConC, CAP210, ZM53M,
CAP45, and ZM233 all became sensitive to neutralization by 1
year and were all characterized by extreme sensitivity to
CAP256 serum, with titers exceeding 1:13,000 at year 3. Anal-
ysis of the sequences showed that all but one of these viruses
had an intact FN/LRD-K-K motif (Fig. 8A). The exception,
ZM53M, had an FN/LRD-K-Q motif, suggesting that 171Q
does not compromise the epitope in this virus.
It was, however, also clear that an FN/LRD-K-K motif was
not sufficient to confer extreme sensitivity to the CAP256
plasma, as four of the seven viruses that became sensitive by
year 2, with moderate peak titers of 1:1,000 to 1:3,500, also
contained a complete FN/LRD-K-K motif (Du422, CAP239,
CAP63, and Du156, Fig. 2 and 8A). The remaining three
viruses in this category had an L165I, an L165V, and/or a
K171N/Q mutation, suggesting that these changes may con-
tribute to the moderate neutralization sensitivity observed.
Thus, the FN/LRD-K-K motif was necessary but not sufficient
for high-level neutralization. In contrast, of the six subtype C
viruses in Fig. 2 which were either resistant or only neutralized
poorly (peak titers of less than 1:200), all contained a minimum
of two mutations within the FN/LRD-K-K motif, with CAP88
containing polymorphisms at four of the seven residues in this
motif.
There was a very striking distinction between the observed
antibody titers against the five most sensitive subtype C viruses
(with peak titers always above 1:13,000) and the next tier of
sensitive subtype C viruses, none of which was neutralized at
titers of 1:3,500. We hypothesized that although the essential
residues that make up the epitope or acceptable substitutions
(e.g., at L165 and K171) might be required for sensitivity,
exposure of the epitope may modulate the titers at which these
viruses were neutralized. In support of this hypothesis, we
observed a statistically significant difference in the length of
the V1 loop when comparing extremely sensitive viruses (ID50,
1:10,000; median V1 loop length of 22 amino acids) with
moderately sensitive viruses (ID50, 1:1,000 to 1:10,000; median
V1 loop length of 30 amino acids) (Fig. 8B, P  0.01). This
suggested that shorter V1 loops exposed the epitope in V2 to
a greater extent or affected its conformation, resulting in in-
creased neutralization titers.
The role of the FN/LRD-K-K motif in subtype A and B
viruses. Similarly, among the five sensitive subtype A viruses,
two (Q259 and Q461) contained the intact FN/LRD-K-K motif
while the remaining three had a single conservative change
which maintained the positive charge at this residue (K169R).
The single resistant subtype A virus contained two deviations
from the FN/LRD-K-K motif, though interestingly, both of
these changes (R166K, a conservative change between posi-
tively charged residues, and K171N) were present individually
in the sensitive (but low-titer) subtype C viruses described
above (Fig. 8A). All of the 12 subtype B viruses, none of which
were neutralized at titers exceeding 1:1,000, had deviations
away from the FN/LRD-K-K motif, primarily but not exclu-
sively at the L165 and K169 residues, the latter being especially
crucial in the ConC mapping described above.
While this variation within the FN/LRD-K-K motif may
contribute to the observed subtype bias in CAP256 neutraliza-
tion, the overall reduced titers even in subtype A viruses that
contained the complete motif suggested that other factors in-
fluenced the sensitivity of these viruses to this plasma. One
possible correlate is suggested by the result obtained for sub-
type C viruses, where viruses with longer V1 loops had lower
titers than those with shorter loops. The increased length of
FIG. 7. Changes in the fine specificity of the V2-dependent nAb present in CAP256 plasma. Longitudinal assessment of the neutralization
sensitivity of CAP45 (parent virus) compared to that of viruses with the F159A, N160A, L165A, R166A, D167N, K169E, and K171E mutations
to CAP256 plasma from 1 to 4 years p.i.
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the V1 loops of sensitive subtype A viruses (median V1 loop
length of 26, P  0.03), compared with those of the extremely
sensitive (titers 1:10,000) subtype C viruses (median V1 loop
length of 22 amino acids), might contribute to the reduced
titers observed in all subtype A viruses. This association was,
however, not significant (P  0.13) when all of the sensitive
subtype C viruses (regardless of titer) were compared with the
sensitive subtype A viruses.
How common is the FN/LRD-K-K motif among viruses of
subtypes A, B, and C? We performed an analysis of the fre-
FIG. 8. The FN/LRD-K-K motif and neutralization sensitivity of subtype C, A, and B viruses. (A) Analysis of the FN/LRD-K-K motif in subtype
C, A, and B viruses (ranked by neutralization sensitivity at 3 years p.i.). Amino acids in blue are positively charged, and those in red are negatively
charged. A point denotes conservation compared to the FNLDRKK motif. (B) Comparison of the V1 loop lengths of subtype C viruses neutralized
at titers exceeding 1:10,000 at 3 years p.i. compared to those neutralized at 1:1,000 to 1:10,000 at the same time point. (C) Analysis of the
frequencies of each residue within the FN/LRD-K-K motif, comparing envelope sequences of subtype C (n  1,375), subtype A (n  746), and
subtype B (n  2,630). Sequences were downloaded from the Los Alamos sequence database.
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quency of the residues comprising the FN/LRD-K-K motif
within the V2 region from 746 subtype A, 2,630 subtype B, and
1,375 subtype C envelope sequences downloaded from the Los
Alamos National Laboratory data bank (http://www.hiv.lanl
.gov). Frequencies of the residues at these positions were plot-
ted using http://weblogo.berkeley.edu (Fig. 8C). This analysis
highlights the conserved nature of the F159 and N160 residues
across all three subtypes (91% across subtypes A, B, and C).
The L165 residue was very conserved in subtype A viruses
(94%) but substantially less conserved in subtype C viruses
(47%) and rare in subtype B viruses (8%), with I165 also well
represented in the latter two subtypes. However, the occa-
sional presence of I165 in sensitive subtype C viruses (Fig. 8A)
suggested that this residue may not have a great impact on
neutralization sensitivity. The R166 residue was present in
99% of the subtype A viruses, compared to 78% and 62% of
the subtype C and B sequences, respectively. Interestingly, in
the sole resistant subtype A virus in our panel (Q769), there
was a highly unusual K166 polymorphism. The D167 residue
was well conserved across the three subtypes but particularly so
in subtypes C and A (97% and 99%, respectively). The residue
which varied the most between the subtypes was K169, which
was present in two-thirds of the subtype C viruses but only a
quarter of the subtype A viruses and less than 10% of the
subtype B viruses. Though the K169 residue is relatively rare in
subtype A viruses, the most common residue in this subtype,
R169, was a conserved change maintaining a positive charge.
In contrast, residue 169 in subtype B viruses was rarely posi-
tively charged. The extreme dependence of neutralization on
residue 169 (as shown by the ConC mapping, Fig. 6B) is likely
an important factor in the subtype preference observed in
neutralization across subtypes A, B, and C. The K171 residue
also varied considerably between subtypes (62% of subtype C
viruses, compared with only 37% of subtype A viruses), but as
polymorphisms at this residue occur in neutralization-sensitive
viruses (e.g., Q171 is present in the highly sensitive subtype C
virus ZM53M [neutralized at a peak titer exceeding 1:10,000])
and is a fairly common polymorphism in subtype C viruses (in
14% of the sequences examined), the significance of this in-
tersubtype variation is less clear.
Introducing the FN/LRD-K-K motif into resistant subtype
A, B, and C viruses. We were interested in determining
whether “repairing” the FN/LRD-K-K motif in resistant vi-
ruses could confer sensitivity. We focused first on the rare
resistant subtype C viruses CAP85 and Du172, as well as
CAP255, which was weakly neutralized via an undefined (but
not anti-V1V2) specificity (Fig. 5, gray panel). Each of these
three subtype C viruses had between one and three substitu-
tions in the FN/LRD-K-K motif. For CAP85, introduction of
the E169K mutation had a dramatic effect on neutralization
sensitivity, with ID50 titers changing from complete neutraliza-
tion resistance (1:45) to greater than 1:40,000, similar to that
seen with the ConC virus (Fig. 9A). Interestingly, this was
despite the presence of 171Q, which, as in the ZM53M virus,
FIG. 9. Restoring the FN/LRD-K-K motif in neutralization-resistant viruses confers neutralization sensitivity. Resistant subtype C (A), subtype
B (B), and subtype A (C) viruses were mutated to restore the FN/LRD-K-K motif to various degrees. Parental viruses (resistant) are shown in gray.
Mutant viruses are shown in black. Asterisks indicate graphs with differing scales to illustrate lower titers. Sequence changes from the FN/LRD-
K-K motif and mutations introduced are shown below the graphs.
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appeared to be tolerated by these antibodies. Similarly, con-
version to the sensitive phenotype was also seen for CAP255,
where the E169K mutation conferred extreme neutralization
sensitivity. The introduction of a T166R mutation into a third
completely resistant subtype C virus, Du172, made it highly
sensitive, with peak titers of around 1:4,000, despite the pres-
ence of L165I, which was also seen in other sensitive subtype C
viruses.
Similarly, the single subtype A virus which was resistant to
neutralization, Q769, could be made neutralization sensitive
(but at low levels) by an N171K mutation, with no further
sensitivity conferred by repair of a second residue, K166R (a
conservative polymorphism) (Fig. 9B). A resistant subtype B
virus, THRO, which contained three substitutions in the FN/
LRD-K-K motif, was rendered weakly sensitive by the V169K
mutation, though in this case, we did not go on to repair the
165 and 171 residues, both of which had conservative changes
from the FN/LRD-K-K motif (Fig. 9C).
Overall, in all three subtypes, we were able to confer sensi-
tivity, sometimes extreme sensitivity, simply by making a single
mutation within the FN/LRD-K-K motif in the V2 region.
However, as with the neutralization-sensitive viruses, the titers
varied considerably, even in the context of an intact FN/LRD-
K-K motif, with titers ranging from approximately 1:400 to
1:40,000, confirming the role of other factors in modulating
sensitivity. This variation in titers could not be ascribed to the
length of the V1 loops in these cases.
The epitope recognized by CAP256 is distinct from but over-
laps that of PG9/PG16. We were interested in determining
whether the epitope defined by CAP256 plasma overlapped
that of the PG9 and PG16 MAbs. We therefore tested a subset
of mutants either reported to affect neutralization by PG9/
PG16 (43) or shown to affect the neutralization of ConC by
CAP256 plasma. These mutants included the residues forming
the FN/LRD-K-K motif plus residues 168 and 181, which had
a lesser effect (Fig. 6). Like CAP256 plasma, both PG9 and
PG16 were heavily dependent on K169 (this mutation was not
tested by Walker et al. [43]) and somewhat dependent on K171
(Fig. 10). The effect of a mutation at residue 181 on CAP256
serum neutralization was also similar to that observed for PG9/
PG16. Therefore, some similarities between the epitopes rec-
ognized by CAP256, PG9, and PG16 clearly exist.
Interestingly, a mutation abrogating the potential glycosyla-
tion site in V2 (N160A) had a profound affect on PG9 and
PG16 (with a 1,000-fold increase in the IC50) but caused a
more moderate 8-fold reduction in the ID50 in CAP256 (and
had no effect on the neutralization of ZM53M [data not
shown]). Unlike PG9 and PG16, where a L165A or K166A
mutation had little effect, mutating these residues reduced the
CAP256 ID50 more than 14- and 100-fold, respectively. The
adjacent D167N residue also impacted CAP256 neutralization
but not PG9/PG16, and a K168A mutation reduced CAP256
neutralization but in fact enhanced the neutralization of ConC
by PG9/16.
Given the fact that PG9 and PG16 target a quaternary
epitope in V2, like CAP256 plasma antibodies, but were also
dependent on residues in V3, we examined the effect of ConC
V3 mutations on CAP256 neutralization. Both PG9/16 and
CAP256, in the context of the ConC backbone, were slightly
affected by mutations in the V3 loop, with mutations at resi-
dues I305, I309, and F317 having a mild effect on neutraliza-
tion sensitivity (1.5- to 3.1-fold reductions in IC50/ID50). The
I307A mutation affected both PG9/PG16 slightly but had no
discernible effect on CAP256 neutralization. The minor effect
of V3 mutations on PG9/PG16 neutralization of ConC is con-
trary to a previous report (43), where mutations in V3 pro-
foundly affected PG16 (though this effect was reduced for
PG9), suggesting that the V3 dependence may be lessened in
the ConC background. This inconsistency might be related to
the fact that, like Du422, ConC in the monomeric form binds
PG9 to some degree (data not shown). However, the discrep-
ancies in the mapping of critical PG9/PG6 residues in JR-CSF
FIG. 10. Effects of V2 and V3 mutations on CAP256 plasma neutralization compared with that of MAbs PG9 and PG16.
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(43) and ConC suggest the necessity for prudence in extrapo-
lating such data between viruses. In summary, we observed
some features in common between CAP256 and PG9/16 neu-
tralization, but there were also significant differences, suggest-
ing that although the epitopes recognized by these antibodies
overlapped, they were not identical.
DISCUSSION
This study aimed to characterize the BCN activity in
CAP256, an HIV-1 subtype C-infected (and subsequently su-
perinfected) participant enrolled in the CAPRISA Acute In-
fection cohort. CAP256 developed cross-neutralizing activity
by 1 year of infection, which increased in both titer and breadth
over 3 years (with the ID50 against some subtype C viruses
exceeding 1:10,000) before beginning to wane. The specificity
conferring breadth targeted a quaternary (trimer-specific)
epitope that was highly dependent on residues 159 to 171 in the
V2 loop and overlapped the epitopes recognized by MAbs PG9
and PG16 (43). This adds to the growing body of data showing
that antibodies recognizing a quaternary epitope involving V2
have considerable cross-neutralizing capacity and that this
epitope may represent a useful vaccine target.
The question of whether BCN activity is due to a single very
broad antibody (43) or to the accumulation of a limited num-
ber of moderately broad specificities (15, 36, 44) is still con-
troversial, and both scenarios likely exist. In the case of
CAP256, it seems that the vast majority of cross-neutralizing
activity can be attributed to antibodies targeting a single re-
gion, which simplified the mapping of this specificity in a poly-
clonal sample. However, the observations that the V2-depen-
dent response in CAP256 neutralized increasing numbers of
viruses over time and that the fine specificity of the neutralizing
activity of this plasma changed over time suggested two possi-
ble pathways to the evolution of breadth in this individual.
Breadth could be associated with affinity maturation of a single
V2-dependent antibody that evolved over time to become less
dependent on residues aside from R166 and K169, thus ac-
quiring the ability to neutralize an increasing number of het-
erologous viruses. This situation would be similar to that seen
in the subtype A-infected individual from whom somatic vari-
ants PG9 and PG16 were obtained, both antibodies having
been derived by affinity maturation from a single B cell clone
but displaying various potencies and epitope specificities. Al-
ternatively, the BCN antibody response may be composed of
multiple V2-dependent antibodies with overlapping but differ-
ent specificities. This would require the stimulation of multiple
B cell lineages targeting the same region, which could be con-
sidered an exposed immunodominant epitope. This phenom-
enon has been reported in a Zambian subtype C-infected in-
dividual where two unrelated groups of autologous MAbs were
isolated, both of which targeted the V2 region (24). The fact
that in CAP256 a single mutation of either K169E or R166A
completely abolished neutralization perhaps argues for the
affinity maturation hypothesis rather than multiple unrelated
antibodies that coincidentally depend on identical residues.
However, a single mutation also conferred escape from both
unrelated MAbs isolated from the Zambian individual (24). A
more complete understanding of the pathway to evolution of
breadth in CAP256 will depend on the future isolation of
MAbs at multiple time points from this individual.
The factors that favor the development of breadth are not
entirely clear. There appears to be an association between
greater viral loads and BCN activity (30, 35), likely reflecting
the need for ongoing antigenic stimulation of B cells. This is
perhaps also reflected in the association of breadth with the
duration of infection (35), which may be related to the high
level of affinity maturation observed in many broadly reactive
MAbs (43, 46, 47). CAP256 was referred for ARV treatment at
4.5 years after infection and had generally high viral loads
(100,000 copies/ml) over the duration of infection, which
may have contributed to the development of BCN antibodies.
Another factor that has been implicated in the development of
breadth is HIV-1 sequence diversity, with individuals with
greater envelope diversity early in infection developing greater
breadth during chronic infection (30). This observation is sup-
ported by recent data showing that dual infection results in
broader and more potent nAb responses (31). CAP256 was
superinfected in the window between the initial infection and
the development of autologous nAb responses, and recombi-
nation between the two infecting strains resulted in substantial
viral variation over the first year of infection (data not shown).
Therefore, a high level of viral diversity early in infection, in
addition to the high viral loads, may also have driven the
development of breadth in CAP256. The decline in titers ob-
served by 4 years of infection, shortly before the initiation of
ARV therapy, may reflect the lower CD4 counts and absence
of CD4 help.
Mapping of the determinants of CAP256 neutralizing activ-
ity identified seven residues in V2 that contributed to this
epitope, namely, the FN/LRD-K-K motif (ranging from F159
to K171). The presence of this motif was associated with neu-
tralization sensitivity, and increasing numbers of polymor-
phisms at these residues were associated with neutralization
resistance. Deviations from the FN/LRD-K-K motif were par-
ticularly pronounced among subtype B viruses, especially at
residues L165 and K169. The role of this motif in conferring
sensitivity was also confirmed by the finding that some resistant
viruses (of subtypes A, B, and C) could be rendered sensitive
(sometimes extremely so, with titers exceeding 1:10,000) by a
single mutation in the FN/LRD-K-K motif. However, it was
also clear that the existence of this motif was not sufficient to
confer high-level sensitivity, with viruses containing the intact
motif but bearing a relatively long V1 loop being much less
sensitive than those with a shorter V1 loop. The effect of the
V1 loop in modulating neutralization sensitivity may be medi-
ated through shielding of the neutralization epitope; however,
it is also possible that the V1 loop length affects the confor-
mation of distal regions of the envelope, thereby exerting an
indirect influence on neutralization titers. Furthermore, it is
possible that additional conserved residues, which were not
identified here, contribute to the epitope. The observation that
CAP256 neutralization sensitivity is determined by the pres-
ence of crucial residues within the V2 epitope but also by the
length of the adjacent V1 loop was not unexpected. Indeed,
this is similar to 4E10, where the sensitivity of viruses contain-
ing the intact epitope in the MPER may be modulated by
changes elsewhere in the envelope (13). The indirect modula-
tion of sensitivity by other regions of the envelope likely pro-
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vides a means of viral escape from antibodies targeting con-
served regions of the envelope (40), as well as affecting the
sensitivity of heterologous viruses to such specificities.
Unlike the V1 loop, which is likely to be structurally disor-
dered and is very variable in length, the V2 loop contains a
number of subdomains that are very conserved across all sub-
types and shows a greater constraint on the minimum length
tolerated (48). Thus, the ability of antibodies recognizing a
relatively conserved region of V2 to cross-neutralize multiple
subtypes is not unexpected. However, the fact that CAP256
neutralizing activity was especially potent against heterologous
subtype C viruses, less potent but as broadly effective against
subtype A viruses, but only weakly effective against subtype B
viruses suggested that the epitope involved is subtype specific.
The precise determinants of the subtype specificity observed in
CAP256 plasma are difficult to pinpoint. Neutralization by
CAP256 is heavily dependent on K169, which is rarely present
in subtype B viruses, perhaps explaining the weak activity of
this plasma against subtype B viruses. However, PG9/16 MAbs
were also dependent on K169 but, unlike CAP256, cross-neu-
tralized all subtypes equivalently. CAP256 was dependent on a
wider range of residues in V2 than PG9/16 (e.g., R166, D167,
and K168, none of which affected PG9/PG16), suggesting that
the “footprint” of these MAbs may be more focused than that
of CAP256, which may recognize a broader epitope that is less
well maintained across multiple subtypes. However, R166,
D167, and K168 are very well conserved across subtypes A, B,
and C. The existence of subtype-specific epitopes is borne out
by existing MAbs—2G12 and 2F5 fail to neutralize most sub-
type C viruses because of genetic variability in the epitope, and
IgG1b12 neutralizes two-thirds of subtype B and C viruses but
only a third of subtype A viruses (2). Preferential neutraliza-
tion by polyclonal plasma of subtype-matched heterologous
viruses has also been shown by us (32) and others (1, 3, 8, 38,
41). Indeed, within the CAPRISA cohort, all of whose mem-
bers were infected with subtype C viruses, we note significantly
better neutralization of subtype C than of subtype B viruses
(data not shown). Although this has led to suggestions that
vaccines should target locally prevalent subtypes (e.g., a sub-
type C vaccine in sub-Saharan Africa), the existence of anti-
bodies targeting all subtypes (e.g., PG9/PG16, VRC01) per-
haps obviates this need. At any rate, a greater understanding of
the determinants of subtype-specific epitopes within the V2
region is required, especially if HIV-1 vaccine immunogen
design becomes more focused on this region.
The increasing interest in antibodies targeting QNEs similar
to PG9 and PG16 has led to the use of N160 mutants to screen
for such specificities (7, 44). However, this approach may be
affected by the various effects of this mutation within different
viruses. The effect of an N160A mutation in ConC on CAP256
neutralization sensitivity was moderate (with an 8-fold reduc-
tion in sensitivity). In contrast, within the context of the
ZM53M envelope, an N160A mutation did not abrogate neu-
tralization; in fact, neutralization was slightly enhanced. The
context dependence of this mutation is not specific to CAP256,
as similar observations were made by Walker et al. (44), who
made an N160A mutation in five viruses and saw various ef-
fects on neutralization by individual plasmas, ranging from
abrogation to enhancement. Furthermore, CAP256 was af-
fected by mutations at both N160 and L165. The effect of these
mutations was considered to represent separate specificities in
a recent analysis of polyclonal sera, with those specificities
sensitive to N160 mutation considered to be PG9/PG16 like,
and distinct from L165A-sensitive antibodies (44). However,
assuming that a single specificity mediates breadth in this case,
CAP256 spans both of these categories, suggesting caution in
interpreting such data as being due to unrelated antibodies.
The development of BCN activity in CAP256, targeting a
subtype-specific epitope existing within the trimeric form of
the envelope, adds to a growing body of data suggesting that
QNEs may represent fairly common neutralization targets in
HIV-1-infected individuals. The extremely high titers observed
in CAP256 also highlight the potential potency of such speci-
ficities. This finding confirms the existence of potential vaccine
targets in this region of the envelope that should be further
investigated in immunogenicity studies.
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